Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

Richard E. Clark(University of Liverpool), I. Anthony Dodi(University of Liverpool), Seran C. Hill(University of Liverpool), Jennie R. Lill(University of Liverpool), Geraldine Aubert(University of Liverpool), Andrew R. Macintyre(University of Liverpool), José M. Rojas(University of Liverpool), Audrey Bourdon(University of Liverpool), Philip Bonner(University of Liverpool), Lihui Wang(University of Liverpool), Stephen E. Christmas(University of Liverpool), Paul Travers(University of Liverpool), Colin S. Creaser(University of Liverpool), Robert C. Rees(University of Liverpool), J. Alejandro Madrigal(University of Liverpool)
Blood
November 15, 2001
Cited by 249Open Access
Full Text

Abstract

The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML). Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA-associated expression of the BCR-ABL peptide KQSSKALQR on class I-negative CML cells transfected with HLA-A*0301, and on primary CML cells from HLA-A3-positive patients. These patients mounted a cytotoxic T-lymphocyte response to KQSSKALQR that also killed autologous CML cells, and tetramer staining demonstrated the presence of circulating KQSSKALQR-specific T cells. The findings are the first demonstration that CML cells express HLA-associated leukemia-specific immunogenic peptides and provide a sound basis for immunization studies against BCR-ABL.


Related Papers

No related papers found

Powered by citation graph analysis